TNNC2

Across TCGA pan-cancer cohorts, TNNC2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TNNC2 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TNNC2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TNNC2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, LSCC, and UCEC are the cancer types where TNNC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.696	0.299	.033	3	view →
LSCC	DFS	Quartile	All	0.815	0.362	.047	2	view →
UCEC	OS	Median	All	0.878	1.000	.047	2	view →
HNSC	DFS	Quartile	III,IV	0.861	0.522	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TNNC2–LUAD (DFS)

Open the LUAD breakdown →